Log in

NASDAQ:ARRYArray Biopharma Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$47.85
0.00 (0.00 %)
(As of 07/30/2019)
Add
Compare
Today's Range
$47.85
Now: $47.85▼
$47.85
50-Day Range
$47.85
MA: $47.85▼
$47.85
52-Week Range
$12.56
Now: $47.85▼
$47.98
Volume206,508 shs
Average Volume4.99 million shs
Market Capitalization$10.68 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.7
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer and other diseases in North America, Europe, and the Asia Pacific. It provides BRAFTOVITM (encorafenib) capsules in combination with MEKTOVI (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF mutation. The company's lead clinical programs include encorafenib and binimetinib that are investigated in approximately 30 clinical trials for various solid tumor indications, including a Phase III trial in BRAF-mutant colorectal cancer. Its product pipeline also includes ipatasertib, an AKT inhibitor that is in Phase III trial to treat prostate or breast cancers; selumetinib, a MEK inhibitor for cancer; larotrectinib, a PanTrk inhibitor that is in a Phase II/registration clinical trial for cancer; tucatinib, a HER2 inhibitor for breast cancer, which is in Phase II/registration trial; and ARRY-797 that is in Phase III clinical trial for Lamin A/C-related dilated cardiomyopathy. In addition, the company is developing varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric cancer; ARRY-382, a CSF1R inhibitor that is in Phase II clinical trial to treat cancer; motolimod/VTX-2337, a Toll-like receptor that is in Phase II clinical trial for cancer; and prexasertib/LY2606368, a CHK-1 inhibitor, which is in multiple Phase I or II clinical trials for cancer. Further, its drug candidates in Phase I clinical trials include GDC-0575, a CHK-1 inhibitor for cancer; LOXO-292, a RET inhibitor to treat cancer; and LOXO-195, a Trk inhibitor for cancer. Additionally, its drug candidates include Ganovo/danoprevir, a protease inhibitor for hepatitis C virus. The company was founded in 1998 and is headquartered in Boulder, Colorado.
Read More
Array Biopharma logo

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.73 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ARRY
Previous Symbol
CUSIP04269X10
CIK1100412
Webwww.arraybiopharma.com
Phone303-381-6600

Debt

Debt-to-Equity Ratio0.45
Current Ratio5.70
Quick Ratio5.65

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$173.77 million
Price / Sales61.44
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.04 per share
Price / Book46.01

Profitability

EPS (Most Recent Fiscal Year)($0.73)
Net Income$-147,340,000.00
Net Margins-52.64%
Return on Equity-48.51%
Return on Assets-24.15%

Miscellaneous

Employees298
Outstanding Shares223,130,000
Market Cap$10.68 billion
Next Earnings DateN/A
OptionableOptionable

Receive ARRY News and Ratings via Email

Sign-up to receive the latest news and ratings for ARRY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Array Biopharma (NASDAQ:ARRY) Frequently Asked Questions

How were Array Biopharma's earnings last quarter?

Array Biopharma Inc (NASDAQ:ARRY) announced its quarterly earnings results on Tuesday, October, 30th. The biopharmaceutical company reported ($0.12) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.22) by $0.10. The biopharmaceutical company earned $56.91 million during the quarter, compared to analysts' expectations of $34.47 million. Array Biopharma had a negative return on equity of 48.51% and a negative net margin of 52.64%. The firm's quarterly revenue was up 91.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.22) EPS.
View Array Biopharma's earnings history.

Has Array Biopharma been receiving favorable news coverage?

News stories about ARRY stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Array Biopharma earned a coverage optimism score of -1.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the next several days.
View the latest news about Array Biopharma.

Who are some of Array Biopharma's key competitors?

Some companies that are related to Array Biopharma include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX).
View all competitors.

What other stocks do shareholders of Array Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Array Biopharma investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Medivation (MDVN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Continental (UAL), Exelixis (EXEL), Kite Pharma (KITE) and Omeros (OMER).

Who are Array Biopharma's key executives?

Array Biopharma's management team includes the following people:
  • Mr. Ron Squarer, CEO & Director (Age 52)
  • Mr. Jason Haddock, Chief Financial Officer (Age 49)
  • Mr. Andrew R. Robbins, Chief Operating Officer (Age 43)
  • Dr. Victor Sandor, Chief Medical Officer (Age 53)
  • Dr. Nicholas A. Saccomano, Chief Scientific Officer (Age 60)

What is Array Biopharma's stock symbol?

Array Biopharma trades on the NASDAQ under the ticker symbol "ARRY."

What is Array Biopharma's stock price today?

One share of ARRY stock can currently be purchased for approximately $47.85.

How big of a company is Array Biopharma?

Array Biopharma has a market capitalization of $10.68 billion and generates $173.77 million in revenue each year. The biopharmaceutical company earns $-147,340,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis. Array Biopharma employs 298 workers across the globe.

What is Array Biopharma's official website?

The official website for Array Biopharma is www.arraybiopharma.com.

How can I contact Array Biopharma?

Array Biopharma's mailing address is 3200 Walnut Street, Boulder CO, 80301. The biopharmaceutical company can be reached via phone at 303-381-6600 or via email at [email protected]

This page was last updated on 8/5/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.